AstraZeneca Announced COVID-19 Vaccine Vaxzevria Authorised for Emergency Use in Japan
AstraZeneca's (NYSE: AZN) COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.
